Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long read ...

PacBio agreed to acquire Omniome for approximately $600 million upfront consisting of 9.4 million shares of PacBio common stock and $300 million in cash—plus up to $200 million in cash and stock ...

PacBio and Intus Bio have launched GutID, the first commercial human gut health test, showcasing their collaboration and innovation in microbiome research. GutID utilizes PacBio's HiFi sequencing ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, recently announced the availability of a new computational analysis method — Tandem Repeat Genotyping Tool (TRGT ...

PacBio has recently introduced new products that are expected to drive strong growth and improve gross margins over the next four to five years. The new products are the materialization of the ...

Illumina and PacBio have terminated their merger agreement in the face of regulatory opposition. Illumina is clearly interested in the long-term potential of long-read sequencing and is likely to ...

Updates since PacBio's last earnings release Initiated a company-wide restructuring plan to reduce operating expenses and sharpen our strategic focus to concentrate resources on the long-read ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, recently announced preliminary revenues for first-quarter 2024. Despite the soft preliminary results, the company’s ...